|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Testa U, Petrucci E, Pasquini L, Castelli
G and Pelosi E: Ovarian cancers: Genetic abnormalities, tumor
heterogeneity and progression, clonal evolution and cancer stem
cells. Medicines (Basel). 5(pii): E162018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meinhold-Heerlein I and Hauptmann S: The
heterogeneity of ovarian cancer. Arch Gynecol Obstet. 289:237–239.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim S, Han Y, Kim SI, Kim HS, Kim SJ and
Song YS: Tumor evolution and chemoresistance in ovarian cancer. NPJ
Precis Oncol. 2:202018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heintz AP, Odicino F, Maisonneuve P, Quinn
MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U:
Carcinoma of the ovary. FIGO 26th annual report on the results of
treatment in gynecological cancer. Int J Gynaecol Obstet. 95 (Suppl
1):S161–S192. 2006. View Article : Google Scholar
|
|
7
|
Berek JS, Kehoe ST, Kumar L and
Friedlander M: Cancer of the ovary, fallopian tube, and peritoneum.
Int J Gynaecol Obstet. 143 (Suppl 2):S59–S78. 2018. View Article : Google Scholar
|
|
8
|
Altman DG and Riley RD: Primer: An
evidence-based approach to prognostic markers. Nat Clin Pract
Oncol. 2:466–472. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gan Y, Li Y, Li T, Shu G and Yin G: CCNA2
acts as a novel biomarker in regulating the growth and apoptosis of
colorectal cancer. Cancer Manag Res. 10:5113–5124. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kulasingam V and Diamandis EP: Strategies
for discovering novel cancer biomarkers through utilization of
emerging technologies. Nat Clin Pract Oncol. 5:588–599. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu J, Meng H, Li S, Shen Y, Wang H, Shan
W, Qiu J, Zhang J and Cheng W: Identification of potential
biomarkers in association with progression and prognosis in
epithelial ovarian cancer by integrated bioinformatics analysis.
Front Genet. 10:10312019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu R, Zhai Y, Kuick R, Karnezis AN, Garcia
P, Naseem A, Hu TC, Fearon ER and Cho KR: Impact of oviductal
versus ovarian epithelial cell of origin on ovarian endometrioid
carcinoma phenotype in the mouse. J Pathol. 240:341–351. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang X, Zhu S, Li L, Zhang L, Xian S, Wang
Y and Cheng Y: Identification of differentially expressed genes and
signaling pathways in ovarian cancer by integrated bioinformatics
analysis. Onco Targets Ther. 11:1457–1474. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Y, Kuick R, Hanash S and Richardson B:
DNA methylation inhibition increases T cell KIR expression through
effects on both promoter methylation and transcription factors.
Clin Immunol. 130:213–224. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gomes Ferreira M, Sancho de Salas M,
González Sarmiento R and Doyague Sánchez MJ: Changes in the
management and prognosis of ovarian cancer due to the new FIGO and
WHO classifications: A case series observational descriptive study.
Seven years of follow-up. Int J Gynecol Cancer. 28:1461–1470. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zeppernick F and Meinhold-Heerlein I: The
new FIGO staging system for ovarian, fallopian tube, and primary
peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Y, Xiang J, Bhandari A, Guan Y, Xia
E, Zhou X, Wang Y and Wang O: CLDN10 is associated with papillary
thyroid cancer progression. J Cancer. 9:4712–4717. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liao J, Li J, Cheng H, Chen Y and Mo Z:
CLDN10 single nucleotide polymorphism rs1325774 alters the risk of
breast cancer in south chinese women. Medicine (Baltimore).
97:e131872018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang GW, Ding X, Chen SL and Zeng L:
Expression of claudin 10 protein in hepatocellular carcinoma:
Impact on survival. J Cancer Res Clin Oncol. 137:1213–1218. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nordfors K, Haapasalo J, Sallinen PK,
Haapasalo H and Soini Y: Expression of claudins relates to tumour
aggressivity, location and recurrence in ependymomas. Histol
Histopathol. 28:1137–1146. 2013.PubMed/NCBI
|
|
24
|
Zhang Z, Wang A, Sun B, Zhan Z, Chen K and
Wang C: Expression of CLDN1 and CLDN10 in lung adenocarcinoma in
situ and invasive lepidic predominant adenocarcinoma. J
Cardiothorac Surg. 8:952013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chattopadhyay I, Singh A, Phukan R,
Purkayastha J, Kataki A, Mahanta J, Saxena S and Kapur S:
Genome-wide analysis of chromosomal alterations in patients with
esophageal squamous cell carcinoma exposed to tobacco and betel
quid from high-risk area in India. Mutat Res. 696:130–138. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barros-Filho MC, Marchi FA, Pinto CA,
Rogatto SR and Kowalski LP: High diagnostic accuracy based on
CLDN10, HMGA2, and LAMB3 transcripts in papillary thyroid
carcinoma. J Clin Endocrinol Metab. 100:E890–E899. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Osanai M, Takasawa A, Murata M and Sawada
N: Claudins in cancer: Bench to bedside. Pflugers Arch. 469:55–67.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nichols LS, Ashfaq R and Iacobuzio-Donahue
CA: Claudin 4 protein expression in primary and metastatic
pancreatic cancer: Support for use as a therapeutic target. Am J
Clin Pathol. 121:226–230. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chao YC, Pan SH, Yang SC, Yu SL, Che TF,
Lin CW, Tsai MS, Chang GC, Wu CH, Wu YY, et al: Claudin-1 is a
metastasis suppressor and correlates with clinical outcome in lung
adenocarcinoma. Am J Respir Crit Care Med. 179:123–133. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Resnick MB, Konkin T, Routhier J, Sabo E
and Pricolo VE: Claudin-1 is a strong prognostic indicator in stage
II colonic cancer: A tissue microarray study. Mod Pathol.
18:511–518. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tokés AM, Kulka J, Paku S, Szik A, Páska
C, Novák PK, Szilák L, Kiss A, Bögi K and Schaff Z: Claudin-1, −3
and −4 proteins and mRNA expression in benign and malignant breast
lesions: A research study. Breast Cancer Res. 7:R296–R305. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo Y, Lin D, Zhang M, Zhang X, Li Y, Yang
R, Lu Y, Jin X, Yang M, Wang M, et al: CLDN6-induced apoptosis via
regulating ASK1-p38/JNK signaling in breast cancer MCF-7 cells. Int
J Oncol. 48:2435–2444. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou S, Piao X, Wang C, Wang R and Song Z:
Identification of claudin-1, −3, −7 and −8 as prognostic markers in
human laryngeal carcinoma. Mol Med Rep. 20:393–400. 2019.PubMed/NCBI
|
|
34
|
Kominsky SL, Argani P, Korz D, Evron E,
Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP and Sukumar S:
Loss of the tight junction protein claudin-7 correlates with
histological grade in both ductal carcinoma in situ and invasive
ductal carcinoma of the breast. Oncogene. 22:2021–2033. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Honda H, Pazin MJ, D'Souza T, Ji H and
Morin PJ: Regulation of the CLDN3 gene in ovarian cancer cells.
Cancer Biol Ther. 6:1733–1742. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gao M, Li W, Wang H and Wang G: The
distinct expression patterns of claudin-10, −14, −17 and E-cadherin
between adjacent non-neoplastic tissues and gastric cancer tissues.
Diagn Pathol. 8:2052013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tabariès S and Siegel PM: The role of
claudins in cancer metastasis. Oncogene. 36:1176–1190. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang X, Wang X, Wang A, Li Q, Zhou M and
Li T: CLDN10 promotes a malignant phenotype of osteosarcoma cells
via JAK1/Stat1 signaling. J Cell Commun Signal. 13:395–405. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Willis BC and Borok Z: TGF-beta-induced
EMT: Mechanisms and implications for fibrotic lung disease. Am J
Physiol Lung Cell Mol Physiol. 293:L525–L534. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhan T, Rindtorff N and Boutros M: Wnt
signaling in cancer. Oncogene. 36:1461–1473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Arend RC, Londoño-Joshi AI, Straughn JJ Jr
and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A
review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS,
Hwang SG, An S, Yoon G, Gye MC, Yi JM, et al: Claudin-1 induces
epithelial-mesenchymal transition through activation of the
c-Abl-ERK signaling pathway in human liver cells. Oncogene.
32:4873–4882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu X, Xiao J, Zhao C, Zhao C, Han Z, Wang
F, Yang Y, Jiang Y and Fang F: Claudin1 promotes the proliferation,
invasion and migration of nasopharyngeal carcinoma cells by
upregulating the expression and nuclear entry of β-catenin. Exp
Ther Med. 16:3445–3451. 2018.PubMed/NCBI
|
|
44
|
Sun H, Cui C, Xiao F, Wang H, Xu J, Shi X,
Yang Y, Zhang Q, Zheng X, Yang X, et al: miR-486 regulates
metastasis and chemosensitivity in hepatocellular carcinoma by
targeting CLDN10 and CITRON. Hepatol Res. 45:1312–1322. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
He Y, Liu J, Wang Y, Zhu X, Fan Z, Li C,
Yin H and Liu Y: Role of miR-486-5p in regulating renal cell
carcinoma cell proliferation and apoptosis via TGF-β-activated
kinase 1. J Cell Biochem. 120:2954–2963. 2019. View Article : Google Scholar : PubMed/NCBI
|
